IL6 and type 2 diabetes mellitus: At one year of follow-up after CABG, the non-SGLT2-I users over-expressed, compared to SGLT2-I users and non-T2DM, the serum inflammatory markers (IL-1, IL-6, and TNF-α; p < 0.05).